The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | NEO-Nal-IRI: liposomal irinotecan + 5-FU & oxaliplatin in panceratic cancer
Brian H. Ramnaraign, MD, University of Florida College of Medicine, Gainesville, FL, outlines the ongoing NEO-Nal-IRI study, a Phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in the preoperative treatment of pancreatic adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
